NCT05912465 (LUCAPET) is a NA clinical trial of Stress Reduction Training in Cachexia, sponsored by Medical University of Vienna.

Who is sponsoring NCT05912465?

NCT05912465 is sponsored by Medical University of Vienna.

What drugs are being tested in NCT05912465?

Interventions in NCT05912465: Stress Reduction Training.

What condition does NCT05912465 study?

NCT05912465 studies Cachexia, Lung Neoplasm.

Is NCT05912465 still recruiting?

NCT05912465 is currently status unknown. Last updated 27 June 2023.

Last reviewed 2023-06-27 · How we verify

NCT05912465: LUCAPET

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Predicting Lung Cancer-Associated Cachexia With PET Imaging

Status unknown NA Last updated 27 June 2023

What this trial tests

NA trial testing Stress Reduction Training in Cachexia in 150 participants. Status unknown.

Timeline

1 July 2023

Primary endpoint
1 July 2024

1 March 2025

Quick facts

Lead sponsor	Medical University of Vienna
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	150
Start date	1 July 2023
Primary completion	1 July 2024
Estimated completion	1 March 2025
Sites	3 locations across Austria, Germany, Italy

Drugs / interventions tested

Stress Reduction Training

Conditions studied

Cachexia — all drugs for Cachexia →
Lung Neoplasm — all drugs for Lung Neoplasm →

Sponsor

Medical University of Vienna

Who can join

18 and older, any sex, with Cachexia or Lung Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This prospective observational study aims to investigate the relationship between cancer cachexia, stress levels, and metabolic changes in 150 lung cancer patients. Cancer cachexia, characterized by weight loss and muscle wasting, significantly impacts patient outcomes. Psychological stress is thought to contribute to cachexia development. Assessments will include medical history, physical examinations, laboratory tests, and imaging. Cancer cachexia will be diagnosed based on weight loss, reduced food intake, and inflammation markers. Psychological stress will be evaluated using questionnaires and biomarkers. Metabolic changes will be assessed using positron emission tomography-computed tomography (PET-CT) scans. The primary objective is to determine differences in metabolic activity between cachectic and non-cachectic patients. Secondary objectives include evaluating changes in brain activity and exploring the relationship between stress, inflammation, and metabolism.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Systemic Metabolic and Volumetric Assessment via Whole-Body [<sup>18</sup>F]FDG-PET/CT: Pancreas Size Predicts Cachexia in Head and Neck Squamous Cell Carcinoma.
Yu J, Spielvogel C, Haberl D, Jiang Z, et al · · 2024 · cited 6× · PMID 39409971 · DOI 10.3390/cancers16193352

Verify or expand the search:

Other recruiting trials for Cachexia

Currently open trials in the same condition.

NCT07083557 — Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiome · recruiting
NCT07338487 — A Clinical Study of Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Cervical Canc · Phase 1 · recruiting
NCT07288619 — Therapeutic Efficacy of Nutritional Supplementation in Cachexia Associated With Chronic Pulmonary Disease · NA · active not recruiting
NCT06989437 — A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Signif · Phase 2, PHASE3 · recruiting
NCT07130981 — Body Composition and Psychosocial Factors in ICI-Treated Cancer Patients · recruiting

Other Medical University of Vienna trials

Trials by the same sponsor.

NCT07473401 — Retinal Oxygen Metabolism in Children With Myopia · not yet recruiting
NCT07511400 — The Role of NaV1.8 in Human Pain Models · EARLY_PHASE1 · not yet recruiting
NCT07516990 — Intramuscular Injection of Mashed Parathyroid Tissue Into a Forearm During Thyroid Surgery to Prevent Permanent Postoper · NA · recruiting
NCT07496437 — Is Cross-linked Hyaluronic Acid a Biologic Alternative for Alveolar Ridge Preservation? · NA · not yet recruiting
NCT07290712 — Post-Intensive Care Syndrome - Multicentre Prospective Registry Database of the DACH Region · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05912465 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University of Vienna
Last refreshed: 27 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05912465.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing